Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06201624
Other study ID # ZU-IRB#10462/26-2-2023
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 1, 2023
Est. completion date May 31, 2024

Study information

Verified date December 2023
Source Zagazig University
Contact Hagar Nofal, Dr.
Phone +201006387707
Email hagarnofal@aucegypt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Melasma is a common refractory acquired hyperpigmentation of the skin having a serious impact on patients' quality of life. Melasma is challenging to treat. Treatment is often a multimodality approach. Due to the attached psychological and social stress, it is important to counsel patients with melasma adequately about the chronicity of the disease, the importance of photoprotection, and the role of hormones in disease persistence before embarking on therapeutic correction. So in this study, we are exploring the efficacy of oral isotretinoin for treating melasma.


Description:

Melasma has a significant impact on the quality of life and self-esteem of those affected. Darker skin photo types e.g. Egyptians have excess potential to develop melasma. Melasma is a chronic and challenging condition to manage. Previous treatment modalities have been unsatisfactory. Oral isotretinoin is a potential treatment modality for melasma that has not been investigated yet. In this study we aim to evaluate the efficacy and the tolerability of oral isotretinoin in the treatment of melasma and to compare its efficacy and tolerability with the current gold standard "topical triple combination formula"


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Age between 18 and 50 years 2. Patients complaining of melasma. 3. Patients with all types of melasma (epidermal, dermal and mixed) 4. Sexually active women who is willing to follow at least 2 types of contraceptive methods during study period 5. Patients with skin type I-V Exclusion Criteria: 1. Pregnant or nursing women. 2. Women on any concurrent therapy for melasma. 3. Patients that are using any therapy for melasma for the last 45 days. 4. Patient with abnormal liver function test or lipid profile. 5. Patients with allergy or hypersensitivity to the assigned drugs. 6. Women not willing to follow contraceptive methods at time of study. 7. Patients on facial treatments or photosensitizing drugs within previous 6 months. 8. Patients with back or joint pain. 9. Patients with pre-existing or dormant dermatologic disease on the face that could interfere with the outcome of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Isotretinoin
Patients will receive 1mg/kg/day for 3 months
Triple combination formula
Patients are instructed to apply the triple combination formula at night daily for 3 months

Locations

Country Name City State
Egypt Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University Zagazig Select Region

Sponsors (1)

Lead Sponsor Collaborator
Zagazig University

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Artzi O, Horovitz T, Bar-Ilan E, Shehadeh W, Koren A, Zusmanovitch L, Mehrabi JN, Salameh F, Isman Nelkenbaum G, Zur E, Sprecher E, Mashiah J. The pathogenesis of melasma and implications for treatment. J Cosmet Dermatol. 2021 Nov;20(11):3432-3445. doi: 10.1111/jocd.14382. Epub 2021 Aug 19. — View Citation

Garner ML, McShane DB, Burkhart CN, Morrell DS. Isotretinoin and vitiligo: can chronic cheilitis cause koebnerization? Pediatr Dermatol. 2015 May-Jun;32(3):e108-9. doi: 10.1111/pde.12538. Epub 2015 Mar 17. — View Citation

Muthu SK, Narang T, Saikia UN, Kanwar AJ, Parsad D, Dogra S. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016 Sep;55(9):1048-54. doi: 10.1111/ijd.13293. Epub 2016 Apr 7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Response to treatment Treatment efficacy will be assessed by the change in disease severity measured in mMASI at the end of the treatment period, and the difference in the global appearance of melasma through standardized photographs using Global Aesthetic Improvement Scale (GAIS) using a five-point ordinal scale (1 = exceptionally improved appearance, 2 = very improved appearance, 3 = improved appearance, 4 = unaltered appearance, 5 = worsened appearance). The duration taken till complete clearance will be assessed as well. three months
Primary Time to complete clearance The duration taken till complete clearance will be assessed as well. 12 weeks
Secondary Quality of life index The change in patients' quality of life using the difference between results of "Melasma Quality of Life Index" at baseline and end of treatment. 12 weeks
Secondary Treatment tolerability Treatment tolerability will be assessed in terms of the side effects reported by the investigator or the patients in follow-up visits including but not limited to; facial erythema, scaling, a burning sensation, and cheilitis. Patients' compliance assessed by the percentage of patients withdraw from each arm of the study and the number of days per week the patients' take/apply their medication. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma N/A
Recruiting NCT06174545 - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma N/A
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Recruiting NCT06278948 - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma N/A
Not yet recruiting NCT05911698 - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. N/A
Recruiting NCT05656833 - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma N/A
Recruiting NCT04597203 - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Terminated NCT03415685 - Lutronic PicoPlus Exploratory Clinical Trial N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Completed NCT04137263 - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging N/A
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT05969587 - Cysteamine Compared to Hydroquinone in Melasma Phase 3
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT05887219 - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Phase 1
Completed NCT05884151 - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Phase 1
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3